Sera Prognostics, Inc. (SERA)
NASDAQ: SERA · Real-Time Price · USD
6.03
-0.15 (-2.43%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States.
The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.
It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.
The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Evguenia Lindgardt |
Contact Details
Address: 2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109 United States | |
| Phone | 801 990 0520 |
| Website | seraprognostics.com |
Stock Details
| Ticker Symbol | SERA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001534969 |
| CUSIP Number | 81749D107 |
| ISIN Number | US81749D1072 |
| Employer ID | 26-1911522 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Evguenia Lindgardt M.B.A. | President, Chief Executive Officer and Director |
| Austin Aerts | Chief Financial Officer |
| Dr. John J. Boniface Ph.D. | Chief Scientific Officer |
| Dr. Gregory C. Critchfield M.D., M.S. | Executive Director |
| Robert G. Harrison | Chief Information Officer |
| Benjamin G. Jackson J.D. | General Counsel |
| Dr. Paul Kearney Ph.D. | Chief Data Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 13, 2024 | 144 | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |